Patents by Inventor Rudolf M. T. de Wildt
Rudolf M. T. de Wildt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210017293Abstract: The present invention relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g. fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains e.g. human immunoglobulin (antibody) single variable domains, and also single variable domains derived from non-human sources such as a llama or camel, e.g. a VHH including a Nanobody™ (described in e.g. WO 94/04678 and WO 95/04079 inter alia). The invention further relates to uses, formulations, compositions comprising such modified C terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these molecules.Type: ApplicationFiled: September 8, 2020Publication date: January 21, 2021Inventors: Claire Ashman, Mary Birchler, Rudolf M.T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
-
Patent number: 10808040Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.Type: GrantFiled: August 13, 2012Date of Patent: October 20, 2020Assignee: Glaxo Group LimitedInventors: Claire Ashman, Mary Birchler, Rudolf M. T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
-
Publication number: 20170210814Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed arc the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: March 27, 2017Publication date: July 27, 2017Inventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 9629909Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: June 18, 2013Date of Patent: April 25, 2017Assignee: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20140227259Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.Type: ApplicationFiled: August 13, 2012Publication date: August 14, 2014Applicant: Glaxo Group LimitedInventors: Claire Ashman, Mary Birchler, Rudolf M.T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
-
Publication number: 20130309227Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: June 18, 2013Publication date: November 21, 2013Applicant: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Greogory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8497244Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: January 23, 2012Date of Patent: July 30, 2013Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8236931Abstract: An inhibitor of the aggregation of immunoglobulin chains is provided. The inhibitor may comprise or consist of a polypeptide which comprises or consists of (a) an amino acid sequence corresponding to the amino acid sequence of the FR1 region of an immunoglobulin light chain variable domain, or part thereof which includes amino acid residue 12, (b) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of bacterial superantigen Protein L, or part thereof, and/or (c) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of streptococcal protein G, or part thereof, or a variant, fusion or derivative thereof, or a fusion of a variant or derivative thereof which retains the ability of the parent polypeptide to inhibit aggregation of immunoglobulin chains, or domains thereof. Other versions of the inhibitor are also provided.Type: GrantFiled: October 26, 2007Date of Patent: August 7, 2012Assignee: Glaxo Group LimitedInventors: Rudolf M. T. De Wildt, Leo C James, Philip C Jones, Oliver Schon, Gregory Paul Winter
-
Publication number: 20120114651Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: January 23, 2012Publication date: May 10, 2012Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8129503Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: October 23, 2006Date of Patent: March 6, 2012Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20110236380Abstract: Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating IL-13-mediated conditions, such as lung conditions, eg allergic asthma, is described. The ligands have potent IL-13 binding kinetics. Ligands are described that are cross-reactive between human IL-13 and one or more primate IL-13. Ligands are well expressed in prokaryotic cells.Type: ApplicationFiled: December 17, 2008Publication date: September 29, 2011Inventors: Rudolf M. T. De Wildt, Inusha De Silva, Milan Ovecka
-
Publication number: 20110159003Abstract: Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.Type: ApplicationFiled: January 24, 2007Publication date: June 30, 2011Applicant: Domantis LimitedInventors: Ian Tomlinson, Allart Adriaan Stoop, Armin Sepp, Inusha De Silva, Caroline J. Dimech, Malgorzata Pupecka, Rudolf M.T. De Wildt, Philip D. Drew, Steve Holmes
-
Patent number: 7696320Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: GrantFiled: January 11, 2006Date of Patent: April 13, 2010Assignee: Domantis LimitedInventors: Olga Ignatovich, Steve Holmes, Roland Beckmann, Rudolf M. T. de Wildt
-
Publication number: 20100056439Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: ApplicationFiled: December 5, 2006Publication date: March 4, 2010Applicant: DOMANTIS LIMITEDInventors: Roland Beckmann, Rudolf M T De Wildt, Steve Holmes, Olga Ignatovich, Laurent S Jespers, Haiqun Liu, Malgorzata Pupecka, Armin Sepp, Michael Steward
-
Publication number: 20100034831Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: October 23, 2006Publication date: February 11, 2010Inventors: Rudolf M.T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20090155283Abstract: The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1? and/or IL-1?) to the receptor but do not inhibit binding of IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resistand dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand.Type: ApplicationFiled: November 30, 2006Publication date: June 18, 2009Inventors: Philip D. Drew, Rudolf M.T. de Wildt, Ian M. Tomlinson, Amrik Basran
-
Publication number: 20090081233Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: ApplicationFiled: July 9, 2008Publication date: March 26, 2009Applicant: Domantis LimitedInventors: Olga Ignatovich, Steve Holmes, Roland Beckmann, Rudolf M.T. de Wildt, Armin Sepp
-
Publication number: 20090060916Abstract: Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.Type: ApplicationFiled: May 15, 2008Publication date: March 5, 2009Inventors: Inusha De Silva, Caroline J. Dimech, Malgorzaa Pupecka, Rudolf M. T. de Wildt
-
Publication number: 20080311111Abstract: The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1? and/or IL-1?) and IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resist and dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand.Type: ApplicationFiled: November 30, 2006Publication date: December 18, 2008Inventors: Philip D. Drew, Rudolf M.T. De Wildt, Ian M. Tomlinson, Amrik Basran